HBM Holdings Doses First Patients in Phase II SIRIUS COPD Study of Ultra Long-Acting Anti-TSLP Antibody HBM9378/WIN378 1
HBM Holdings: First Patients Dosed in Phase II SIRIUS COPD S...
Sign in to continue:
HBM Holdings: First Patients Dosed in Phase II SIRIUS COPD S...
Minieye Technology Announces Landmark Autonomous Vehicle Pro...
Century Entertainment International Holdings Limited: Furthe...
China Jinmao Holdings Group Limited - May 2026 Sales Data ...
Qyuns Therapeutics Announces Significant Share Repurchase Pr...
Wong’s Kong King International (Holdings) Limited Announces ...
Parkson Retail Group Limited Announces Book Closure for Extr...
Shenzhen Edge Medical Announces HK\$200 Million Share Repurc...
Longfor Group Announces May 2026 Operating Statistics and La...
Broker: BCA Research Inc. Date of Report: June 8, 2026 Excer...